297 related articles for article (PubMed ID: 32100585)
1. An overview of binimetinib for the treatment of melanoma.
Specenier P
Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585
[TBL] [Abstract][Full Text] [Related]
2. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with
Sullivan RJ; Weber J; Patel S; Dummer R; Carlino MS; Tan DSW; Lebbé C; Siena S; Elez E; Wollenberg L; Pickard MD; Sandor V; Ascierto PA
Clin Cancer Res; 2020 Oct; 26(19):5102-5112. PubMed ID: 32669376
[TBL] [Abstract][Full Text] [Related]
3. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
[TBL] [Abstract][Full Text] [Related]
4. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
5. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
6. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H
Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370
[TBL] [Abstract][Full Text] [Related]
7. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
Rose AAN
Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
[TBL] [Abstract][Full Text] [Related]
8. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
[TBL] [Abstract][Full Text] [Related]
9. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
Trojaniello C; Festino L; Vanella V; Ascierto PA
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
[TBL] [Abstract][Full Text] [Related]
10. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
11. The discovery and development of binimetinib for the treatment of melanoma.
Tran B; Cohen MS
Expert Opin Drug Discov; 2020 Jul; 15(7):745-754. PubMed ID: 32249628
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients.
Indini A; Mandalà M
Expert Opin Drug Saf; 2020 Oct; 19(10):1229-1236. PubMed ID: 32857940
[TBL] [Abstract][Full Text] [Related]
13. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
14. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
15. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
Dinter L; Karitzky PC; Schulz A; Wurm AA; Mehnert MC; Sergon M; Tunger A; Lesche M; Wehner R; Müller A; Käubler T; Niessner H; Dahl A; Beissert S; Schmitz M; Meier F; Seliger B; Westphal D
Int J Cancer; 2024 Mar; 154(6):1057-1072. PubMed ID: 38078628
[TBL] [Abstract][Full Text] [Related]
16. Binimetinib for the treatment of NRAS-mutant melanoma.
Queirolo P; Spagnolo F
Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
Gogas H; Dummer R; Ascierto PA; Arance A; Mandalà M; Liszkay G; Garbe C; Schadendorf D; Krajsová I; Gutzmer R; Sileni VC; Dutriaux C; Yamazaki N; Loquai C; Queirolo P; Jan de Willem G; Sellier AT; Suissa J; Murris J; Gollerkeri A; Robert C; Flaherty KT
Eur J Cancer; 2021 Jul; 152():116-128. PubMed ID: 34091420
[TBL] [Abstract][Full Text] [Related]
18. Development of encorafenib for BRAF-mutated advanced melanoma.
Koelblinger P; Thuerigen O; Dummer R
Curr Opin Oncol; 2018 Mar; 30(2):125-133. PubMed ID: 29356698
[TBL] [Abstract][Full Text] [Related]
19. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussein M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
Future Oncol; 2024; 20(16):1047-1055. PubMed ID: 38357801
[TBL] [Abstract][Full Text] [Related]
20. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable
Schadendorf D; Dummer R; Robert C; Ribas A; Sullivan RJ; Panella T; McKean M; Santos ES; Brill K; Polli A; Pietro AD; Ascierto PA
Future Oncol; 2022 Jun; 18(17):2041-2051. PubMed ID: 35272485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]